Suffer from a rare disorder in Canada? Good luck: Nigel Rawson and John Adams in the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
Tag: drug pricing
The Patented Medicine Prices Review Board has lost its way (again)
By W. Neil Palmer November 1, 2022 PDF of commentary The Patented Medicine Prices Review Board (PMPRB) is once again ...
The kindest cut: Excising the Patented Medicine Prices Review Board from the Canadian body politic
By Richard C. Owens, Rebecca Rosenberg, and Haya Sardar June 2, 2022 PDF of paper Executive Summary Canada’s drug price ...
National drug plan process doesn’t add up: Nigel Rawson in The Hamilton Spectator
This article originally appeared in the Hamilton Spectator. By Nigel Rawson, February 23, 2022 Theatre of the Absurd features plays ...
Webinar panel video: Pandemic resilience and access to new drugs and vaccines in the COVID era
With two years of COVID-19 experience and uncertainty around the omicron variant, it is clear that prompt access to new ...
False Premise – Federal Regulation of Drug Prices as a Step to National Pharmacare: Rawson and Adams in National Newswatch
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
Appeal court exposes PMPRB abuse of power and bias on drug pricing: Nigel Rawson and John Adams in the Financial Post
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
Quebec gets the constitution right (on drug price control): Richard Owens in the Financial Post
While unconstitutional institutions and policies may be accommodated by the provinces to some degree, pushing them too far will end ...
Use COVID pause to reconsider drug-price regulation: Nigel Rawson and John Adams in the Financial Post
Canadians need Ottawa to work with the pharmaceutical industry, clinicians and patients to improve access to new medicines and vaccines, ...
COVID-19 Highlights Weaknesses in Canada’s System for New Medicines: MLI report by Rawson and Adams
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world ...
MLI experts available to comment on delay to federal drug price reduction scheme
OTTAWA, ON (June 2, 2020): Changes to the Patented Medicine Prices Review Board (PMPRB) have been delayed until January 2021 ...
Government refuses to address real cause of missing cystic fibrosis treatment in Canada: Nigel Rawson in National Newswatch
Nothing fair exists in denying Canadian cystic fibrosis patients approved and funded access to treatments that they have been waiting ...
Top News
-
The Rupture Cycle – Commodities, geopolitics, and Canada’s moment: Heather Exner-Pirot
-
Rebalancing Canada: A two-pillar reform of equalization and federal transfers
-
Canada’s conversation about new submarines is failing to ask the most important question: Rob Huebert in The Globe and Mail
-
The most overlooked aspect of the new West Coast pipeline could be the most consequential: Jack Mintz in The Hub
-
A threat from within – Why NATO should suspend Türkiye: Isabelle Terranova
